UniQure's Huntington's gene therapy readout expected before the end of September

UniQure PLC is expected to report four-year results from its Huntington’s disease gene therapy trial before the end of September, according to STAT News. The readout has been closely tracked within the field of programmable biological interventions, where long-term durability data remain scarce.

The Huntington’s program has drawn particular scrutiny because the disease’s progressive, well-characterized course gives researchers a relatively clear yardstick against which to measure any slowing of decline. A four-year window is unusually long for gene therapy follow-up, and STAT News notes that investors and clinicians alike are watching for whether early signals of benefit, reported in smaller or shorter analyses, persist at this later stage.

STAT News’s account frames the upcoming disclosure as a test of durability rather than of initial efficacy alone. The publication reports that questions remain about trial design, patient selection, and how any observed effects might be interpreted given the small size of Huntington’s trial populations generally.

No results have yet been made public. The report describes the coming weeks as the point at which UniQure has indicated it will share the four-year data, without specifying an exact date. STAT News’s preview draws on the company’s prior public statements and previously reported earlier-stage results from the same trial, without disclosing further specifics ahead of the formal announcement.